Clinical Study Synopsis for Public Disclosure
|
|
- Grant Ross
- 5 years ago
- Views:
Transcription
1 abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical study report - had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion. The synopsis may include approved and non-approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities. A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country. Additional information on this study and the drug concerned may be provided upon request based on s Policy on Transparency and Publication of Clinical Study Data. The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of. V1.0/2014
2 Pharmaceuticals, Inc. BI Trial No.: Page 3 12 January March 2004 to 09 February 2012 Title of study: Investigator: A Phase I open-label dose escalation study of once-daily oral treatment with for 21 days in patients with advanced solid tumors Study centers: Multicenter study, cf. Appendix Publication (reference): Clinical phase: Objectives: Methodology: Stopfer P, Schaefer HG, Amelsberg A, Huisman H, Eskens F, Gietema JA, Briscoe J, Lewis N, Cohen RB, Marshall J, Verweij J,. Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. AACR-NCI-EORTC Int Conf 'Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications', Philadelphia, Nov Abstr. B172 (R ). Marshall JL, Lewis NL, Amelsberg A, Briscoe J, Hwang J, Malik S, Cohen R,. A phase I dose escalation study of, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. AACR-NCI-EORTC Int Conf 'Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications', Philadelphia, Nov 2005 Clin Cancer Res 2005;11(23)(Suppl):168 Abstr B161 (R ). Stopfer P, Schaefer HG, Amelsberg A, Huisman H, Eskens F, Gietema JA, Briscoe J, Lewis N, Cohen RB, Marshall J, Verweij J,. Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. AACR-NCI-EORTC Int Conf 'Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications', Philadelphia, Nov Abstr. B172 (P ). I The primary objective was the assessment of safety of as assessed by the maximum tolerated dose (MTD). Secondary objectives were collection of overall safety data, antitumor efficacy data, as well as the determination of pharmacokinetics and the pharmacodynamic modulation of biomarkers by. Open-label, dose escalation study
3 Pharmaceuticals, Inc. BI Trial No.: Page 4 12 January March 2004 to 09 February 2012 No. of subjects: planned: enrolled: 54 entered: 45 actual: enrolled: 49 entered: 43 Treatment A: 10 mg entered: 3 treated: 3 analyzed (for primary endpoint): Treatment B: 20 mg entered: 6 treated: 6 analyzed (for primary endpoint): Treatment C: 40 mg entered: 8 treated: 8 analyzed (for primary endpoint): Treatment D: 55 mg entered: 20 treated: 20 analyzed (for primary endpoint): Treatment E: 65 mg entered: 6 treated: 6 analyzed (for primary endpoint) Diagnosis and main criteria for inclusion: Test product: Test product: dose: mode of admin.: batch no.: Patients with a confirmed diagnosis of a malignant solid tumor refractory or not amenable to standard therapies, preferably patients with breast, colorectal or prostate cancer. tablets Starting dose of 10 mg /day once daily, followed by dose escalation Oral B030902, B040108, B (5 mg); B030905, B040109, B (20 mg) Duration of treatment: Continuous daily dosing for 21 days followed by 7 days off, repeated courses (administration for 21 consecutive days followed by 7 days off ) in the absence of clinical disease progression. Reference therapy: NA dose: mode of admin.: batch no.:
4 Pharmaceuticals, Inc. BI Trial No.: Page 5 12 January March 2004 to 09 February 2012 Criteria for evaluation: Efficacy: Safety: Statistical methods: SUMMARY CONCLUSIONS: Efficacy results: Pharmacokinetic and pharmacodynamic parameters (biomarker modulation in skin and tumor biopsies). Objective tumor response (based on RECIST). Adverse events (AEs) according to common terminology criteria (CTC), laboratory evaluations, patient performance, cardiac left ventricular function, ECG Descriptive statistics of the patient population as well as for pharmacokinetic determinations. Adverse Events were analyzed for first treatment period as well as for all treatment periods combined. Overall, the patient population was consistent with a general Phase I population. The most frequent tumors were colorectal, breast, pancreatic, ovarian, thyroid, esophageal, prostate, and lung cancer. Tumors were evaluated according to RECIST criteria in 39 patients. All patients had at least one prior treatment while most of the patients (84.6%) had three or more prior therapies. Almost 72% of patients with measurable disease had three or more prior chemotherapies. No patient experienced a confirmed objective response. One patient with squamous cell carcinoma of the skin experienced a transient PR with progression at a repeat assessment two treatment cycles later. One patient experienced tumor shrinkage by 13%, which was maintained and the patient entered the roll-over trial.
5 Pharmaceuticals, Inc. BI Trial No.: Page 6 12 January March 2004 to 09 February 2012 Safety results: Forty-three patients were treated at doses of 10, 20, 40, 55, and 65 mg. Gastrointestinal disorders (mainly diarrhea, nausea, vomiting and stomatitis,) and skin adverse events (mainly rash, pruritus, mucosal inflammation and dry skin) were the most frequently reported drug-related AEs. The single most frequently reported AE related to trial medication was diarrhea (65.1%). It generally commenced within 1 week of start of trial medication but occasionally occurred only in later treatment courses when lower doses were administered. The onset of skin-related events is later than that of diarrhea (mainly in the second week of treatment). The incidence of stomatitis appears to dose-related. In Treatment Period 1 (TP1) there appears to be a relationship between the incidence of drug-related diarrhea and the dose of. This relationship was not maintained when all treatment periods were analyzed together. Events of epistaxis were seen at a higher frequency than expected. A similar finding has been made in the study (administration of for 2 weeks followed by a 2 week drug-free period in repeated cycles). Epistaxis was mostly observed at higher dose levels. Severity of epistaxis was always low (CTC Grade 1), and the duration was generally brief. Supportive treatment was not required. A correlation between epistaxis or other bleeding events and coagulation parameters (especially PT, PTT) was not found. Most patients did not exhibit significant changes in liver enzymes over the conduct of this study. For the smaller number of patients demonstrating more pronounced elevations in transaminases, the events were primarily observed after discontinuation of during the post-treatment period. The most likely interpretation for these increases in liver transaminases was a progression of the underlying disease (either primary liver carcinoma or liver metastases from colorectal or breast cancer disease). A number of patients experienced a pronounced decline in previously elevated transaminases. Other clinically relevant changes in a limited number of patients were reversible increase in serum creatinine, hyponatremia, and hypokalemia. Some of these changes were associated with the occurrence of diarrhea and/or vomiting. Decreases in body weight may have been associated with gastrointestinal AEs but may also have been related to the course of the patient s disease. There was some reversible decline in hemoglobin, which may have been the result of multiple blood draws. There have been occasional changes in lymphocyte counts without a clear cause. Similar changes have also been seen in animal studies. Coagulation parameters changed in some patients and did not appear to be correlated with bleeding events. A correlation of changes in coagulation with the treatment seemed unlikely.
6 Pharmaceuticals, Inc. BI Trial No.: Page 7 12 January March 2004 to 09 February 2012 There was no decrease in LVEF to CTC Grade 2 during the conduct of study observed. No important changes in vital signs and ECGs were noted. A trend toward increasing severity of AEs with increasing dose was observed, which seemed to be relevant for cases of diarrhea and rash. The incidence of drug-related AEs seemed to increase when patients receive more than one course of treatment with. Fifteen patients (34.9%) experienced one or more SAEs. There were 10 deaths, two during screening period, three during the treatment period and five in the post-treatment period. A total of 5 patients died due to disease progression. None of these cases were considered to be related to the trial medication. Seven patients discontinued from the trial as a result of AEs. In total, 11 patients developed DLT in TP1. The most common DLT event was diarrhea (5 patients). This protocol defined the MTD based on DLT events reported during TP1 of the dose-escalation phase of this trial. While DLT events were observed in 3/6 (50%) patients in the 65 mg cohort, only one DLT event was observed in the initial group of 6 patients at 55 mg. According to the protocol, 55 mg was the MTD group to be further evaluated in an expansion cohort. During the conduct of the expansion cohort, an additional 6 patients developed DLT events exceeding a pre-set limit in the protocol. The further enrolment into this dose cohort was discontinued. An expansion cohort below 55 mg was not evaluated. For Phase II clinical trials a daily dose below 55 mg (e.g., 40 mg) should be evaluated. It may be considered to aggressively treat diarrhea or to prescribe antidiarrheal medication prophylactically. In general, AEs observed in this trial were consistent with the safety profile of other EGFR inhibitors, although the rate of epistaxis has been higher.
7 Pharmaceuticals, Inc. BI Trial No.: Page 8 12 January March 2004 to 09 February 2012 Pharmacokinetics: exhibited similar disposition kinetics after both single and multiple administrations and could be described by at-least biexponential disposition kinetics. After oral administration of, maximum plasma concentrations were mostly detected between 2-5 hours post-drug administration. Generally, maximum plasma concentrations and exposure increased with increasing doses after single administration and at steady state. For, all PK parameters displayed moderate to high variability in all treatment cohorts, both after single dose and at steady state, but this was within the expected range for an orally administered anti-cancer drug in the first Phase I dose finding study. The gmean terminal half-life following oral administration of ranged between 20 hours and 43 hours. However, the terminal half-life determination for was more reliable on Day 21 of TP1. Therefore, the terminal half-life of is likely in the range of 35 hours to 43 hours. Pharmacodynamics: A relatively high apparent total body clearance and volume of distribution for was determined. The values obtained for total body clearance and volume of distribution should be treated with caution as the absolute bioavailability of in humans is unknown. Steady state was reached, at latest, within 8 days after the first administration of. The gmean accumulation ratios based on Cmax values were between 1.36 and Based on AUC values gmean accumulation ratio values were approximately 1.81 to treatment significantly reduced the proliferation rate of epidermal keratinocytes, with a concordant increase in epidermal keratinocyte differentiation. Furthermore, there might be a correlation between the clinically used treatment doses and the level of inhibition of epidermal keratinocyte proliferation and the accompanied induction of epidermal keratinocyte differentiation. No significant changes in any of the other studied biomarkers were observed.
8 Pharmaceuticals, Inc. BI Trial No.: Page 9 12 January March 2004 to 09 February 2012 Conclusions: In summary, has an AE profile that is consistent with other EGFR and EGFR / HER2 inhibitors. The MTD is 55 mg once daily, although a lower dose (e.g., 40 mg/day) may be used in subsequent trials in a schedule with 21 days on treatment followed by a 7 day drug-free period in repeated cycles. Preliminary signs of clinical efficacy, with tumor shrinkage and one transient partial response, have been observed. At 16 weeks of treatment, the Kaplan-Meier estimate was that 25.2% of patients at the MTD were alive and free of disease progression. This compares favorably to other compounds evaluated in Phase I settings. The PK profile is acceptable and skin biopsies have shown a pharmacodynamic modulation of epidermal keratinocytes as expected from a drug inhibiting the EGFR inhibitor. Based on the findings in this trial, the further evaluation of in clinical trials is warranted.
This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSynopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02
Module 5.3 Protocol: EudraCT No.: 2004-002130-18 Title of the study: A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationCabozantinib (Cometriq )
Cabozantinib (Cometriq ) Workshop dose escalation EMA 4/5 Dec 2014 Frans Opdam, internist-clinical pharmacologist Clinical assessor, Dutch Medicines Agency Phase 3 Study XL184-301 (EXAM): Design Cabozantinib
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationASCO Annual Meeting 2013, May 31 June , Chicago, IL
Phase I Study of Safety and Pharmacokinetics of GDC-0917, an Antagonist of Inhibitor of Apoptosis Proteins in Patients with Refractory Solid Tumors or Lymphoma 1 A Tolcher, 1 K Papadopoulos, 1 A Patnaik,
More informationPhase 1 Trial of ALN-VSP in Cancers Involving the Liver. Annual Meeting of the Controlled Release Society August 2, 2011
Phase 1 Trial of ALN-VSP in Cancers Involving the Liver Annual Meeting of the Controlled Release Society August 2, 2011 Agenda ALN-VSP: Background Phase 1 Trial Study Design Safety Data Tumor Response
More informationGIOTRIF (AFATINIB*) For journalists outside the US/UK/Canada only 1. WHAT IS GIOTRIF (AFATINIB*)? 2. HOW DOES GIOTRIF (AFATINIB*) WORK?
For journalists outside the US/UK/Canada only GIOTRIF (AFATINIB*) 1. What is GIOTRIF (afatinib*)? 2. How does GIOTRIF (afatinib*) work? 3. Data overview 4. Clinical potential 5. GIOTRIF (afatinib*) approval
More informationINNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB
INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI 23-24 GIUGNO 2005 Policlinico Universitario - Cagliari LAPATINIB Elena Massa CATTEDRA DI ONCOLOGIA MEDICA UNIVERSITA DEGLI STUDI DI CAGLIARI ErbB Inhibition
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationRECRUITMENT OF PATIENTS
Newsletter This resume of the results from the phase 1b study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationProduct: Darbepoetin alfa Clinical Study Report: Date: 22 August 2007 Page 2 of 14145
Date: 22 ugust 2007 Page 2 of 14145 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C, US Name of Finished Product: ranesp Name of ctive Ingredient: Darbepoetin alfa Title of Study: Randomized,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationBackgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?
Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationAFATINIB* 1. WHAT IS AFATINIB? 2. HOW DOES AFATINIB WORK? B A C K G R O U N D E R
AFATINIB* B A C K G R O U N D E R 1. What is afatinib? 2. How does afatinib work? 3. Data overview: the LUX-Lung clinical trial programme 4. Data overview: the LUX-Head and Neck clinical trial programme
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPrincipal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom
SYNOPSIS Issue Date: 14 October 2010 Document No.: EDMS-ERI-13494974:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: COU-AA-BE Cougar Biotechnology, Inc.
More informationPBI-05204, an inhibitor of Akt, FGF-2, NF-κb and p70s6k
PBI-05204, an inhibitor of Akt, FGF-2, NF-κb and p70s6k S. Bidyasar, R. Kurzrock, G. S. Falchook, A. Naing, J. J. Wheler, J. Durand, P. Yang, M. J. Johansen, R. A. Newman, R. Khan, D. Hong MD Anderson
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationSponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug
More informationONT-380 and HER2+ Breast Cancer
ONT-380 and HER2+ Breast Cancer Diana F. Hausman, MD CMO, VP Clinical Development Oncothyreon Inc. PNW Bio February 10 2015 Copyright 2014 Copyright Oncothyreon 2014 Oncothyreon Oncothyreon Leading Oncology
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Phase 1b Multicenter Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationProduct: Blinatumomab (AMG 103) Clinical Study Report: MT Date: 19 April 2013 Page 2 of 9510
Date: 19 April 2013 Page 2 of 9510 2. SYNOPSIS Name of Sponsor: Amgen Research (Munich), formerly Micromet AG/Micromet GmbH, Staffelseestrasse 2, 81477 Munich, Germany Name of Finished Product: Blinatumomab
More informationSynopsis. Clinical Report Synopsis for Protocol Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Synopsis Clinical Report Synopsis for Protocol 197-02-220 Name of Company: Otsuka Pharmaceutical Development & Commercialization, Inc. Name of Product: Tetomilast (OPC-6535) Study Title: A Phase 3, Multicenter,
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationTitle of Study: Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
SYNOPSIS Name of Sponsor/Company Name of Finished Product REMINYL Name of Active Ingredient(s) Galantamine hydrobromide Issue Date: 18 October 2013 Protocol No.: Title of Study: Evaluation of Efficacy
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More information